Combination Therapy with Pyridoxine and Arginine Supplementations along with a Lysine-Restricted Diet in Individuals with Pyridoxine-Dependent Epilepsy: A Comprehensive Systematic Review

dc.contributor.authorJafari, Ali
dc.contributor.authorMehdi Abbasi, Mohammad
dc.contributor.authorAbbasi, Hamid
dc.contributor.authorRahnemayan, Sama
dc.contributor.authorBakhshimoghaddam, Farnush
dc.contributor.authorDoaei, Saeid
dc.date.accessioned2025-09-01T06:42:22Z
dc.date.available2025-09-01T06:42:22Z
dc.date.issued2025-07-08
dc.date.updated2025-08-28T14:33:43Z
dc.description.abstractBackground: Pyridoxine-dependent epilepsy (PDE) is identified as a rare neurometabolic disease marked by biallelic pathogenic mutations of the ALDH7A1 gene. A combination therapy involving pyridoxine, arginine supplementation (AS), and a lysine-restricted diet (LRD) was frequently reported to effectively improve PDE through reducing neurotoxic lysine metabolites, improving seizure management, and enhancing neurodevelopmental outcomes. Objectives: The study sought to investigate the effects of mono-(pyridoxine), dual-(pyridoxine combined with AS or LRD), and triple-therapy approaches in individuals diagnosed with PDE. Methods: An extensive search was carried out across international databases, comprising Scopus, Embase, Web of Science, PubMed, and Google Scholar, to find relevant publications published before 12 November, 2024. The methodological quality assessment of chosen articles was evaluated utilizing the Newcastle-Ottawa Scale and the Joanna Briggs Institute tool. Results: Among 2097 studies reviewed, 38 met inclusion criteria, covering treatment methods for individuals with PDE including mono-therapy (22 articles), dual therapy (9 articles), and triple therapy (7 articles). The results indicated that pyridoxine monotherapy is a highly effective first-line treatment in PDE that improves seizure control with minimal cognitive decline. Combining pyridoxine with an LRD or AS targets metabolic issues, reducing neurotoxic metabolites and enhancing cognitive and motor functions. Early triple therapy, within the first 6 months of life, exhibited significant benefits for seizure management and cognitive performance in patients with PDE. Conclusions: In summary, administration of pyridoxine is highly effective, particularly when combined with AS and an LRD. Triple therapy illustrates promise for improved seizure control and cognitive function, especially when initiated early. Further research is warranted.
dc.format.extent18 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2475-2991
dc.identifier.pmid40800672
dc.identifier.urihttps://hdl.handle.net/2445/222854
dc.language.isoeng
dc.publisherElsevier BV
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.cdnut.2025.107504
dc.relation.ispartofCurrent Developments in Nutrition, 2025, vol. 9, num. 8, 107504
dc.relation.urihttps://doi.org/10.1016/j.cdnut.2025.107504
dc.rightscc-by (c) Jafari, Ali et al., 2025
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationEpilèpsia
dc.subject.classificationVitaminoteràpia
dc.subject.otherEpilepsy
dc.subject.otherVitamin therapy
dc.titleCombination Therapy with Pyridoxine and Arginine Supplementations along with a Lysine-Restricted Diet in Individuals with Pyridoxine-Dependent Epilepsy: A Comprehensive Systematic Review
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
PIIS2475299125029658.pdf
Mida:
1.74 MB
Format:
Adobe Portable Document Format